Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2377
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor) ; volume:15 ; number:1 ; day:23 ; month:6 ; year:2015 ; pages:1-11 ; date:12.2015
BMC neurology ; 15, Heft 1 (23.6.2015), 1-11, 12.2015
- Creator
- Contributor
-
Grützke, Berit
Eveslage, Maria
Deppe, Michael
Gross, Catharina C.
Kirstein, Lucienne
Posevitz-Fejfar, Anita
Schneider-Hohendorf, Tilman
Schwab, Nicholas
Meuth, Sven
Wiendl, Heinz
SpringerLink (Online service)
- DOI
-
10.1186/s12883-015-0354-9
- URN
-
urn:nbn:de:1111-2016110510793
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Klotz, Luisa
- Grützke, Berit
- Eveslage, Maria
- Deppe, Michael
- Gross, Catharina C.
- Kirstein, Lucienne
- Posevitz-Fejfar, Anita
- Schneider-Hohendorf, Tilman
- Schwab, Nicholas
- Meuth, Sven
- Wiendl, Heinz
- SpringerLink (Online service)
Other Objects (12)
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Relapsing/remitting type 1 diabetes
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Prediction of prognosis and response to fingolimod in people with relapsing-remitting multiple sclerosis
Endocarditis following ocrelizumab in relapsing-remitting MS
Postural Control in Relapsing-Remitting Multiple Sclerosis
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Relapsing/remitting type 1 diabetes
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Prediction of prognosis and response to fingolimod in people with relapsing-remitting multiple sclerosis
Endocarditis following ocrelizumab in relapsing-remitting MS
Postural Control in Relapsing-Remitting Multiple Sclerosis
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Relapsing/remitting type 1 diabetes
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Prediction of prognosis and response to fingolimod in people with relapsing-remitting multiple sclerosis
Endocarditis following ocrelizumab in relapsing-remitting MS
Postural Control in Relapsing-Remitting Multiple Sclerosis
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study